Colospan
Kfar Saba
About Colospan
Colospan is a clinical-stage medical device company developing proprietary technology for colorectal surgery to prevent anastomotic leaks and diverting colonic stomas. It has developed a product that protects the intestine after a colectomy and sealing of the intestine, which is performed in cases of severe intestinal inflammatory disease and cancer of the bowel or rectum. In places where the intestine has been sealed, leakage requiring prolonged hospitalization or repeat surgery on already weak patients is liable to occur. The company develops a device that prevents inner-body leaks after intestinal surgery. It also develops a silicone-based, tube-like device intended to prevent the leak of feces into the body cavity after surgery in the intestines or colon. Colospan's device is meant to prevent or delay the for need colostomy’the surgical creation of an external bypass for the intestine or colon following the removal of a diseased part. The company’s lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site. Colospan was founded in 2010 and is based in Kefar Sava, Israel.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $18.6M
- Last round: Series Unknown (Dec 2021)
- Website: colospan.com
- Phone: +97297672518
Industries & Categories
Biotechnology, Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/colospan-111722 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.